European Journal of Clinical Pharmacology

, Volume 33, Issue 1, pp 21–25 | Cite as

Comparison of concomitant nicardipine hydrochloride and propranolol with propranolol alone in patients with essential hypertension

  • J. G. Nievel
  • C. W. H. Havard
  • A. P. Douglas-Jones
Originals

Summary

A twelve-week parallel study was conducted to compare the efficacy and safety of nicardipine plus propranolol with that of propranolol alone in 67 patients with mild to moderate essential hypertension. Efficacy data was analysed for 50 patients. The regimens used were 90 mg · day−1 of nicardipine and 120 mg · day−1 of propranolol.

Both treatments significantly reduced supine and standing systolic and diastolic blood pressure from baseline values at all visits. At all visits, concomitant administration of nicardipine and propranolol produced a greater reduction in systolic and diastolic pressures than did propranolol alone, although the difference between treatments did not always reach statistical significance.

Few adverse events were reported, and none was clinically important.

We conclude that nicardipine taken concomitantly with propranolol is more effective than propranolol alone in treating patients with hypertension and that the combined regimen is well tolerated.

Key words

nicardipine propranolol hypertension concomitant administration adverse effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Asplund J (1985) Nicardipine hydrochloride in essential hypertension — a controlled study. Br J Clin Pharmacol 20 [Suppl 1]: 120S-124SPubMedGoogle Scholar
  2. Forette F, Bellet M, Henry JF, Hervy MP, Poyard-Salmeron C, Bouchacourt P, Guerret M (1985) Effect of nicardipine in elderly hypertensive patients. Br J Clin Pharmacol 20 [Suppl 1]: 125S-129SPubMedGoogle Scholar
  3. Forthofer RN, Lehnen RG (1981) Public program analysis: A new categorical data approach. Lifetime Learning Publications, Belmont, CaliforniaGoogle Scholar
  4. Fujita T, Noda H (1983) Hemodynamic changes associated with long-term antihypertensive therapy with new calcium antagonist. Jpn Heart J 24: 587–593PubMedGoogle Scholar
  5. Grizzle JE, Starmer CF, Koch GG (1969) Analysis of categorical data by linear models. Biometrics 25: 489–504PubMedCrossRefGoogle Scholar
  6. Guazzi MD (1982) The role of calcium antagonists in the management of hypertension. Pract Cardiol 8: 39–55Google Scholar
  7. Hollander M, Wolfe DA (1973) Nonparametric statistical methods. John Wiley and Sons, New YorkGoogle Scholar
  8. Kaplan NM (1983) Newer anti-hypertensive agents. Postgrad Med 73: 213–215, 219–222PubMedGoogle Scholar
  9. Kolloch R, Stumpe KO, Overlack A (1985) Blood pressure, heart rate and A-V conduction responses to nicardipine in hypertensive patients receiving atenolol. Br J Clin Pharmacol 20 [Suppl 1]: 130S-134SPubMedGoogle Scholar
  10. Lambert CR, Hill JA, Nicholas WW, Feldman RL, Pepine CJ (1985) Coronary and systemic hemodynamic effects of nicardipine. Am J Cardiol 55: 652–656PubMedCrossRefGoogle Scholar
  11. Levenson J, Simon ACh, Bouthier J, Maarek BC, Safar ME (1985) The effect of acute and chronic nicardipine therapy on forearm arterial haemodynamics in essential hypertension. Br J Clin Pharmacol 20 [Suppl 1]: 107S-113SPubMedGoogle Scholar
  12. Maxwell AE (1961) Analysing qualitative data. Methuen, LondonGoogle Scholar
  13. Messerli FH, Ventura HO (1982) The role of calcium antagonists in hypertension. Drug Ther Hosp 7: 39–44, 48Google Scholar
  14. Nayler WG (1983) Calcium antagonists. Med J Aust 2 (10): 506–512PubMedGoogle Scholar
  15. Nayler WG, Horowitz JD (1983) Calcium antagonists: A new class of drugs. Pharmacol Ther 20 (2): 203–262PubMedCrossRefGoogle Scholar
  16. Pouleur H, Etienne J, Van Mechelen H, Van Eyll C, Charlier AA, Brasseur LA, Rousseau MF (1984) Effects of nicardipine or nifedipine added to propranolol in patients with coronary artery disease. Postgrad Med J 60 [Suppl 4]: 23–28PubMedGoogle Scholar
  17. Rousseau MF, Etienne J, Van Mechelen H, Veriter C, Pouleur H (1984) Haemodynamic and cardiac effects of nicardipine in patients with coronary artery disease. J Cardiovasc Pharmacol 6: 833–839PubMedGoogle Scholar
  18. Spivack C, Ocken S, Frishman WH (1983) Calcium antagonists: Clinical use in the treatment of systemic hypertension. Drugs 25: 154–177PubMedGoogle Scholar
  19. Takabatake T, Ohta H, Yamamoto Y, Maekawa M, Arai S, Hattori N, Nomura G (1982) Antihypertensive effects of nicardipine hydrochloride in essential hypertension. Int J Clin Pharmacol Ther Toxicol 20: 346–352PubMedGoogle Scholar
  20. Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Silke B (1985) Anti-hypertensive dose-response effects of nicardipine in stable essential hypertension. Br J Clin Pharmacol 20 [Suppl 1]: 135S-138SPubMedGoogle Scholar
  21. Zsoter TT, Church JG (1983) Calcium antagonists: Pharmacodynamic effects and mechanisms of action. Drugs 25: 93–112PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • J. G. Nievel
    • 1
  • C. W. H. Havard
    • 1
  • A. P. Douglas-Jones
    • 2
  1. 1.Department of Clinical Pharmacology and TherapeuticsRoyal Northern HospitalLondonEngland
  2. 2.The SurgeryTuckswood, NorwichEngland

Personalised recommendations